Table 3.
Outcome measures | N = 39 patients (47 lesions) | |
---|---|---|
Primary | LLL (mm) | −0.13 ± 0.44 |
Secondary | NLG (mm) | 1.1 ± 0.53 |
Clinical | TLR at 6-month f/u | 1/2a |
MACE at 6-month f/u | 2/3a | |
MACE at 1-year f/u | 2/3a |
Results are shown as per-protocol analysis
LLL late lumen loss, NLG net luminal gain, TLR target lesion revascularization, MACE major adverse cardiovascular events, f/u follow-up
aIntention-to-treat analysis (N = 54 lesions in 46 patients)